Towards Pharmaceutical Products

Currently, the pharmaceutical industry presents many opportunities for electrolytic processes because of the need for new, clean and selective technologies moreover, the markets for products are for relatively low tonnages. Experience shows, however, that the move from a laboratory scale to production often requires the development of new technology and/or rethinking the relative importance of the criteria determining the process economics. 

For scale up [53,54], the reactions presented three main challenges (i) if the anode reaction involves oxidation of the aprotic solvent, a complex mixture of products would result and the system would become very messy (ii) the current density for selective conversion is limited by the solubility of carbon dioxide and (iii) the conductivity of the media is poor. However, these problems were overcome by  

Ultimately, this combination of requirements led to the pencil sharpener cell, in which the magnesium anode was a rod (diameter 40 cm) with one end shaped as the point of a pencil. The shaped part of the anode sat within a conforming, conical cathode (Pb-plated stainless steel), with the electrodes separated by a thin polymer spacer. The weight of the anode ensured that the anode pressed down on the spacer and that the shape was maintained as metal was lost from the anode. The production unit had two such cells, each with an active electrode area of 0.6 m, and was operated with a cell current of 600 A. The operating pressure was 5 bar, and electrolyte was circulated though the cell from a 400 liter reservoir. For the manufacture of fenoprofen the unit was operated in batches, whereby a batch of 60 kg chloroethyldiphenylether was dissolved in 340 kg dimethylformamide that also contained 3 kg tetrabutylammonium bromide. Each batch, when processed for 28 h, led to 50 kg of isolated fenoprofen. The good yield ( 80%) showed the electrolytic route to fenoprofen to be very competitive with more traditional syntheses. 

The Electrosynthesis Co have described [55] the scale-up of a process for a key step in manufacturing the cephalosporin antibiotic, Ceftibuten (marketed by Schering-Plough)  

much of the product development conducted in pharmaceutical company laboratories is carried out in microflow systems that allow a total conversion of reactant to product that is rapid, efficient and selective on a scale of 1-100 g for activity testing. The past few years have seen several groups seek to develop electrolysis cell designs that can be used in such equipment. The Southampton group have attempted to develop cells that combine good performance with an appearance similar to other equipment used for routine microfiow synthesis. This led to a cell based on a single-patterned microchannel, parallel 

---

The National Pharmaceutical Control Bureau shall ensure the quahty and safety of pharmaceutical products through the implementation of the relevant legislation by a competent workforce working together in strategic alliance towards improving the health of the people. ... 

A study of physician attitudes toward capsules and other pharmaceutical product forms. Elanco Products Co., Div. Eli Lilly Co., Indianapolis, IN, 1971, El-0004. 

The approaches and strategies presented in this chapter are intended to overcome these issues for CE methods. Recendy a more advanced approach toward chromatographic method development was introduced in pharmaceutical product development that also is beneficial for CE methods. In the advanced approach (i) the voice of the customer is captured, (ii) key process input variables are identified, (iii) critical to quality (CTQ) factors are determined, (iv) several method verification tests are installed, (v) proactive evaluation of method performance during development is performed, (vi) continuous customer involvement and focus is institutionalized, and (vii) method capability assessment (suitability to be applied for release testing against specification limits) is established. 

The phenolic derivatives of this series, such as aristolochic acid la and 4,5-dioxoaporphine, suffered considerable bathochromic shifts, and further shifts toward the longer wavelength region are observed on addition of alkali. For instance, the UV spectrum of 4,5-dioxoaporphine (49), 246 (4.70), 292 (4.14), 305 (4.26), 318 (4.28), 459 (4.23), shifts to 241 (4.71), 256 (4.67), 305 (4.21), 331 (4.25), 510 (4.30) in alkaline solution (64). This bathochromic shift was also found in aristolochic acid la (50) (63, 65). The UV spectroscopic method has been used for the quantitative analysis of aristolochic acids from plants or pharmaceutical products (66-68,71). 

The critics of government-imposed price controls on pharmaceutical products do have a valid point. As long as the price ceilings are set above the incremental cost of producing these products, manufacturers will be tempted to sell at whatever those controlled prices are, because they earn at least a positive margin toward the recovery of fixed costs. The problem is that the price ceilings may be set at levels far below fully allocated fixed costs per unit. If every payer followed that strategy, pharmaceutical companies would soon become insolvent. 

As emphasized by Reinhardt in Chapter 2, public investment on valuing pharmaceutical products is an important step toward balancing power... 

Taylor, D., and Poulmaire, M., (2008) Poster Presentation Pharmaceutical Products in the Environment Towards Lowering Occurrence and Impact KNAPPE International Conference, Nimes (Prance). 

He has been responsible for pharmaceutical product development from exploratory development, preclinical, preformulation, and drug delivery platform technologies, formulation, process, and scale-up manufacturing toward commercialization. 

Zhao, C., Jain, A., Hailemariam, L., Suresh, P., Akkisetty, P., Joglekar, G., Venkatasubra-manian, V., Reklaitis, G.V., Morris, K., and Basu, P. (2006), Toward intelligent decision support for pharmaceutical product development, I. Pharm. Innovation, 1, 23-35. 

An additional example is the reduction of aromatic nitro compounds to anilines. This reduction is a very important synthetic transformation because the nitro group is often used to activate the aromatic nuclei for nucleophilic substitutions. The amino group, however, is frequently utilized for further derivatization towards valuable products such as pharmaceuticals. 

Mass spectrometry (MS) is playing an increasingly visible role in the molecular characterization of combinatorial libraries, natural products, drug metabolism and pharmacokinetics, toxicology and forensic investigations, and proteomics. Toward this end, electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), and atmospheric pressure photo-ionization (APPI) have proven valuable for both qualitative and quantitative screening of small molecules (e.g., pharmaceutical products) [9-14]. 

The purpose of this article is to provide an overview of the different types of chemical and biological catalysis currently available to the pharmaceutical industry in the process area. In other words, these transformations can be performed at scale. The types of catalysts that have been used are given together with systems that show potential for future application. The chemocatalytic area has addressed the synthesis of aromatic and heterocyclic compounds, which are common classes in pharmaceutically active compounds, whereas biocatalyst applications tend to be aimed toward the production of chiral molecules. 

---